| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Opioid-Related Disorders | |||||
| 2 | More general conditions related to this trial | ||||
| Disorders of Environmental Origin | |||||
| Mental Disorders | |||||
| Substance-Related Disorders | |||||
| 3 | Interventions listed in this trial | ||||
| Buprenorphine | |||||
| 4 | More general drug interventions related to this trial | ||||
| Analgesics | |||||
| Analgesics, Opioid | |||||
| Central Nervous System Agents | |||||
| Central Nervous System Depressants | |||||
| Narcotic Antagonists | |||||
| Narcotics | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Sensory System Agents | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| National Institute on Drug Abuse (NIDA) | |||||
| University of Vermont | |||||
|
